{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T04:24:51Z","timestamp":1769142291807,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,22]]},"DOI":"10.7759\/cureus.102069","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:59:00Z","timestamp":1769090340000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Comparative Efficacy and Safety of Upadacitinib, Tofacitinib, and Filgotinib in Patients With Ulcerative Colitis"],"prefix":"10.7759","author":[{"given":"Fraz","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tausif","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chamith  H","family":"Gunaratne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Collum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Ghaffar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Gharbia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.034","article-title":"Upadacitinib for Crohn's disease and ulcerative colitis treatment: hitting the selective JAKpot","volume":"160","author":"Parigi TL","year":"2021","unstructured":"Parigi TL, D'Amico F, Danese S. Upadacitinib for Crohn's disease and ulcerative colitis treatment: hitting the selective JAKpot. Gastroenterology. 2021, 160:1472-4. 10.1053\/j.gastro.2020.04.034","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.02.013","article-title":"Entering the era of disease modification in inflammatory bowel disease","volume":"162","author":"Hart AL","year":"2022","unstructured":"Hart AL, Rubin DT. Entering the era of disease modification in inflammatory bowel disease. Gastroenterology. 2022, 162:1367-9. 10.1053\/j.gastro.2022.02.013","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan DP","year":"2021","unstructured":"McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021, 398:803-16. 10.1016\/S0140-6736(21)00438-4","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12227132","article-title":"Drug clearance in patients with inflammatory bowel disease treated with biologics","volume":"12","author":"Deyhim T","year":"2023","unstructured":"Deyhim T, Cheifetz AS, Papamichael K. Drug clearance in patients with inflammatory bowel disease treated with biologics. J Clin Med. 2023, 12:7132. 10.3390\/jcm12227132","journal-title":"J Clin Med"},{"key":"ref5","unstructured":"Upadacitinib for treating moderately to severely active ulcerative colitis. (2023). Accessed. 2025: https:\/\/www.nice.org.uk\/guidance\/ta856."},{"key":"ref6","unstructured":"Tofacitinib for moderately to severely active ulcerative colitis. (2018). Accessed. 2025: https:\/\/www.nice.org.uk\/guidance\/ta547."},{"key":"ref7","unstructured":"Filgotinib for treating moderately to severely active ulcerative colitis. (2022). Accessed. 2025: https:\/\/www.nice.org.uk\/guidance\/ta792."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran GW","year":"2025","unstructured":"Moran GW, Gordon M, Sinopolou V, et al.. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut. 2025, 74:s1-s101. 10.1136\/gutjnl-2024-334395","journal-title":"Gut"},{"key":"ref9","unstructured":"Consent in research. (2018). Accessed. 2025: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/policies-standards-legislation\/data-protection-and-information...."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.87903","article-title":"Real-world efficacy of upadacitinib in patients with ulcerative colitis","volume":"17","author":"Ghaffar A","year":"2025","unstructured":"Ghaffar A, Ahmad F, Collum J, Naveed L. Real-world efficacy of upadacitinib in patients with ulcerative colitis. Cureus. 2025, 17:e87903. 10.7759\/cureus.87903","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18406","article-title":"Comparative efficacy and safety of three Janus kinase inhibitors in ulcerative colitis: a real-world multicentre study in Japan","volume":"61","author":"Akiyama S","year":"2025","unstructured":"Akiyama S, Shimizu H, Tamura A, et al.. Comparative efficacy and safety of three Janus kinase inhibitors in ulcerative colitis: a real-world multicentre study in Japan. Aliment Pharmacol Ther. 2025, 61:524-37. 10.1111\/apt.18406","journal-title":"Aliment Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12704","article-title":"Real-world comparative effectiveness and safety of filgotinib and upadacitinib for ulcerative colitis: a multicentre cohort study","volume":"12","author":"Nogami A","year":"2024","unstructured":"Nogami A, Asonuma K, Okabayashi S, et al.. Real-world comparative effectiveness and safety of filgotinib and upadacitinib for ulcerative colitis: a multicentre cohort study. United European Gastroenterol J. 2024, 12:1357-66. 10.1002\/ueg2.12704","journal-title":"United European Gastroenterol J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.07.033","article-title":"Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis","volume":"23","author":"Shehab M","year":"2025","unstructured":"Shehab M, Alrashed F, Alsayegh A, et al.. Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2025, 23:250-62. 10.1016\/j.cgh.2024.07.033","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otad009","article-title":"Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis","volume":"5","author":"Panaccione R","year":"2023","unstructured":"Panaccione R, Collins EB, Melmed GY, et al.. Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis. Crohns Colitis 360. 2023, 5:otad009. 10.1093\/crocol\/otad009","journal-title":"Crohns Colitis 360"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae190.0785","article-title":"P0611 effectiveness comparisons between tofacitinib, filgotinib and upadacitinib in ulcerative colitis: results from the JAKARTA real-world evidence multicenter study","volume":"19","author":"Buisson A","year":"2025","unstructured":"Buisson A, Treton X, Nachury M, et al.. P0611 effectiveness comparisons between tofacitinib, filgotinib and upadacitinib in ulcerative colitis: results from the JAKARTA real-world evidence multicenter study. J Crohns Colitis. 2025, 19:i1211.","journal-title":"J Crohns Colitis"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae190.0792","article-title":"P0618 a network meta-analysis to compare the efficacy of advanced treatments for biological-experienced patients with ulcerative colitis","volume":"19","author":"Kulkarni A","year":"2025","unstructured":"Kulkarni A, Giri S, Joshi H. P0618 a network meta-analysis to compare the efficacy of advanced treatments for biological-experienced patients with ulcerative colitis. J Crohns Colitis. 2025, 19:i1222.","journal-title":"J Crohns Colitis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera PA","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020, 158:1554-1573.e12. 10.1053\/j.gastro.2020.01.001","journal-title":"Gastroenterology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/444938-real-world-comparative-efficacy-and-safety-of-upadacitinib-tofacitinib-and-filgotinib-in-patients-with-ulcerative-colitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:59:02Z","timestamp":1769090342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/444938-real-world-comparative-efficacy-and-safety-of-upadacitinib-tofacitinib-and-filgotinib-in-patients-with-ulcerative-colitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.102069","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}